What if both sides are partly right?
Few topics in menopause generate as much debate as hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT).
Depending on who you listen to, you’ll hear two very different stories. One says hormone therapy is dangerous and significantly increases the risk of breast cancer and cardiovascular events. The other says those fears are outdated, that modern “body-identical” hormones are safe, and that earlier concerns were overstated.
As with many areas of human biology, neither extreme fully reflects the evidence. The real story is not about who was right. It is about how scientific understanding evolves when complexity is gradually uncovered.
Before 2002: HRT as a protective therapy
For decades prior to the early 2000s, hormone therapy was widely viewed as beneficial. Observational studies suggested women using HRT had lower rates of heart disease, fewer fractures and improved overall health outcomes.
As a result, prescribing increased rapidly. But observational research carried an important limitation: women who chose HRT were often systematically different from those who did not. They tended to have higher socioeconomic status, better access to healthcare and healthier baseline lifestyles. This is now recognised as the "healthy user effect".
Stronger evidence was needed to understand cause and effect.
2002: The study that changed the narrative
The Women’s Health Initiative (WHI) was one of the largest randomised controlled trials ever conducted on menopausal hormone therapy, involving 16,608 postmenopausal women aged 50 to 79 years [1].
The combined therapy arm was stopped early after researchers observed increased risks in women receiving oral conjugated equine oestrogens (0.625 mg/day) in combination with medroxyprogesterone acetate (2.5 mg/day), a synthetic progestin. Signals included an increased incidence of breast cancer, cardiovascular events, and thrombotic outcomes.
The public interpretation that followed was that hormone therapy was broadly harmful. Prescribing patterns shifted rapidly worldwide in the years that followed.
The evolution of evidence (2002 → 2026)
Over the following two decades, research shifted from broad conclusions to finer distinctions. Instead of asking “Is HRT safe or unsafe?”, researchers began asking: Does timing of initiation matter? Does route of administration matter? Does type of oestrogen matter? Does type of progestogen matter?
A more nuanced picture gradually emerged.
2000s → “HRT is risky”: Initial interpretation of WHI findings dominated clinical perception.
2010s → “Timing and age may matter”; “Route of administration matters”: Re-analysis of WHI data and emerging cohort studies shifted toward the “timing hypothesis”. Transdermal oestrogen showed lower clotting risk than oral formulations.
2020s → “Not all progestogens behave the same": Synthetic progestins were increasingly associated with stronger adverse breast signals than other forms. Focus expanded to oestradiol, micronized progesterone, and real-world prescribing patterns.
The rise of micronized progesterone
One of the most important developments has been the increased use of micronized progesterone. Unlike synthetic progestins, it is structurally identical to endogenous progesterone, which has led to interest in whether it may have different tissue-level effects. Observational data, including the French E3N cohort [2], have reported lower breast cancer risk signals but less effective in providing endometrial protection, compared with certain synthetic progestins. A systematic review found no increase in breast cancer risk with oestrogen combined with oral micronized progesterone for up to five years of use [3]. However, evidence beyond five years remains limited.
This limitation is important. Most of the available evidence on micronized progesterone comes from observational studies and relatively short-term clinical trials, with follow-up periods generally of less than five years. As a result, we still lack large, long-term randomised controlled trials evaluating modern regimens of oestradiol combined with micronized progesterone over 10 to 20 years.
Risks and benefits coexist
The benefits of menopausal hormone therapy (MHT) are well established, particularly for the management of vasomotor symptoms such as hot flushes and night sweats. Evidence also consistently shows improvements in sleep quality, vaginal and urogenital symptoms, and preservation of bone mineral density.
A benefit-focused meta-analysis of 24 studies involving 5,089 women found that hormone therapy can improve quality of life in symptomatic menopausal women, support vaginal health, increase circulating oestrogen levels, and contribute to improved bone density outcomes [4].
At the same time, the risks are also real and well documented.
A comprehensive global evidence meta-analysis [5], integrating both epidemiological and randomised trial data, has examined breast cancer risk associated with different forms and timing of menopausal hormone therapy. In parallel, a large observational study of approximately 1.3 million women in Norway evaluated breast cancer risk according to hormone therapy type, route of administration, specific compounds, tumour subtype, and mode of detection, using non–hormone therapy users as the reference group [6]. Both studies show an increased risk of breast cancer compared with non-users of MHT. However, the magnitude of this risk is not uniform. Risk varies depending on:
- age at initiation
- time since menopause
- duration of use
- type of oestrogen and progestogen
- route of administration (oral vs transdermal)
- body mass index and underlying metabolic factors
- individual biological and physiological characteristics
Taken together, these findings reinforce an important shift in modern menopause science and clinical practice:
Hormone therapy is not a single uniform intervention, but a spectrum of treatments with differing risk–benefit profiles.
As a result, current clinical guidance increasingly emphasises a personalised approach—balancing age, time since menopause, symptom severity, and individual risk factors to guide decision-making.
The biggest gap in modern menopause science
The central gap in current menopause research is not simply whether hormone therapy is “safe” or “unsafe.” Rather, it is the absence of large, long-term randomised controlled trials specifically evaluating current commonly used regimens (oestradiol plus micronized progesterone) over 10–20 years.
In addition, while emerging research suggests that genetic and biological variability may influence individual responses to hormone therapy, this area remains insufficiently understood. Early evidence indicates that genetic differences in hormone metabolism and receptor activity may contribute to variability in treatment response and risk profiles, but these interactions have not yet been fully characterised in clinical practice.
Until long-term outcome data and a clearer understanding of individual biological variability are available, a degree of uncertainty will remain in guiding truly personalised hormone therapy decisions.
Beyond hormones: building biological resilience
Regardless of how hormone therapy is used, one principle remains consistent across human biology: health is shaped by the function and adaptability of the body’s core regulatory systems.
These include gut microbiome function and metabolic signalling, nervous system regulation and stress resilience, sleep and circadian rhythm stability, and nutritional adequacy alongside inflammatory balance.
These systems influence not only how menopause is experienced, but also how any intervention is tolerated and integrated by the body. No single medication replaces these foundational processes. Rather, they form the biological terrain upon which all therapies act.
While science continues to refine its understanding of hormone therapy, it is equally important to return attention to these fundamental systems and support the body’s inherent capacity for regulation and adaptation—an interconnected biological ecosystem shaped by millions of years of evolution. More detail on how these interconnected systems interact in midlife can be found in our broader discussion of the body’s internal ecosystem.
Like what you're reading? Get our best wellness tips + expert insights — straight to your inbox by staying connected.
Disclaimer - This content is for general informational purposes only and is not intended to imply benefits of any specific product.
References
[1]. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., Ockene, J., & Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321–333.
[2]. Clavel-Chapelon, F., & E3N Study Group. (2015). Cohort profile: The French E3N cohort study. International Journal of Epidemiology, 44(3), 801–809.
[3]. Stute, P., Wildt, L., & Neulen, J. (2018). The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric : the journal of the International Menopause Society, 21(2), 111–122.
[4]. Tang, Y., Ma, R., Zhang, L., Sun, X., & Wang, Y. (2025). Effectiveness and safety of hormone replacement therapy in the treatment of menopausal syndrome: a meta-analysis. American journal of translational research, 17(1), 1–15.
[5]. Collaborative Group on Hormonal Factors in Breast Cancer (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet (London, England), 394(10204), 1159–1168.
[6]. Støer, N. C., Vangen, S., Singh, D., Fortner, R. T., Hofvind, S., Ursin, G., & Botteri, E. (2024). Menopausal hormone therapy and breast cancer risk: A population-based cohort study of 1.3 million women in Norway. British Journal of Cancer, 131(1), 126–137.